Urovant Sciences, Inc and Thinx, Inc Form a Unique Partnership Designed to Educate People Living with The Symptoms of Overactive Bladder (OAB) For Patients With OAB, Traveling or Enjoying
Interim 12-week analysis from the ongoing Phase 2a trial of an investigational novel gene therapy product, URO-902 (plasmid human cDNA encoding maxi-K channel), receives International Continence
Urovant Sciences, Inc. receives Fortuneand Great Place to Work Best Workplaces in BioPharma (2022) recognition. Follows Urovant's Best Place to Work recognition by the Orange County Business
Survey of 71 Directors of Nursing (DONs) highlights a need for improved awareness, education, and management of urinary incontinence (UI) related to overactive bladder (OAB) in long-term care (LTC)